First Trust Advisors LP grew its holdings in Livongo Health (NASDAQ:LVGO) by 7.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 115,522 shares of the company’s stock after purchasing an additional 7,649 shares during the period. First Trust Advisors LP owned about 0.12% of Livongo Health worth $8,686,000 as of its most recent SEC filing.
Several other institutional investors have also bought and sold shares of LVGO. Schroder Investment Management Group grew its holdings in shares of Livongo Health by 0.6% in the first quarter. Schroder Investment Management Group now owns 45,567 shares of the company’s stock worth $1,371,000 after acquiring an additional 280 shares during the period. Watson Rebecca bought a new stake in shares of Livongo Health in the second quarter worth $53,000. Advisor Group Inc. grew its holdings in shares of Livongo Health by 50.4% in the fourth quarter. Advisor Group Inc. now owns 2,911 shares of the company’s stock worth $73,000 after acquiring an additional 975 shares during the period. Evoke Wealth LLC bought a new stake in shares of Livongo Health in the first quarter worth $28,000. Finally, Telemus Capital LLC grew its holdings in shares of Livongo Health by 16.7% in the second quarter. Telemus Capital LLC now owns 7,000 shares of the company’s stock worth $740,000 after acquiring an additional 1,000 shares during the period. 38.94% of the stock is owned by institutional investors and hedge funds.
NASDAQ:LVGO opened at $127.25 on Friday. The company has a market capitalization of $12.45 billion and a P/E ratio of -110.65. Livongo Health has a 12 month low of $15.12 and a 12 month high of $128.41. The business’s 50-day moving average is $88.20 and its 200 day moving average is $49.00.
In other Livongo Health news, insider James Pursley sold 24,857 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $74.37, for a total transaction of $1,848,615.09. Following the sale, the insider now directly owns 98,889 shares of the company’s stock, valued at $7,354,374.93. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Lee Shapiro sold 48,565 shares of the business’s stock in a transaction that occurred on Tuesday, July 21st. The stock was sold at an average price of $113.83, for a total value of $5,528,153.95. Following the sale, the chief financial officer now directly owns 1,899,919 shares in the company, valued at $216,267,779.77. The disclosure for this sale can be found here. Insiders sold 563,574 shares of company stock worth $34,400,243 over the last quarter. 13.00% of the stock is owned by company insiders.
Several analysts recently commented on the company. Needham & Company LLC lifted their price objective on Livongo Health from $70.00 to $120.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Morgan Stanley lifted their price objective on Livongo Health from $62.00 to $89.00 and gave the stock an “overweight” rating in a report on Tuesday, July 7th. Stephens initiated coverage on Livongo Health in a research report on Monday, July 6th. They set an “overweight” rating and a $95.00 target price on the stock. Credit Suisse Group initiated coverage on Livongo Health in a research report on Tuesday, July 14th. They set an “outperform” rating and a $132.00 target price on the stock. Finally, Guggenheim initiated coverage on Livongo Health in a research report on Thursday, April 23rd. They set a “buy” rating and a $46.00 target price on the stock. Four research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $77.95.
About Livongo Health
Livongo Health, Inc provides an integrated suite of solutions for the healthcare industry in North America. It solutions promote health behavior change based on real-time data capture supported by intuitive devices and insights driven by data science. The company offers a platform that provides cellular-connected devices, supplies, informed coaching, data science-enabled insights, and facilitates access to medications.
Recommended Story: Google Finance Portfolio Workaround
Receive News & Ratings for Livongo Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Livongo Health and related companies with MarketBeat.com's FREE daily email newsletter.